PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Overview of the government policy of the Pharmaceutical Industry in Indonesia and possible impact to the business

ACI is pleased to announce that Widyaretna Buenastuti, Public Affairs & Communications Director,Pfizer Indonesia will give a presentation at International Pharma Regulatory Summit, 27th-28th July 2017 in Singapore

Presentation Title: Overview of the government policy of the Pharmaceutical Industry in Indonesia and possible impact to the business

Speaker: Widyaretna Buenastuti, Public Affairs & Communications Director, 

Pfizer Indonesia

If you have any questions for the speaker, please write to us and we would discuss at the summit

Widya started as Public Affairs and Communications Director of Pfizer in 2011. Prior to that, Widya was the Legal Director for Pfizer Indonesia and had given Legal services since 2002 where she joined Pfizer as Legal Manager. During her tenure in Legal, she had a one year experience of managing legal affairs of Pfizer Singapore (2010 – 2011).

In her current role, one of her responsibility is to ensure Pfizer’s good reputation in the eye of its stakeholders be maintained. In addition to her roles in Pfizer, she has been asked by the external stakeholders to also take part and lead the Indonesian Anti-Counterfeiting Society or known in Indonesia abbreviation as MIAP. She holds the chairmanship of this association since 2008 and since then has increased the awareness from the stakeholders to jointly combat counterfeit. Various partnerships with stakeholders have been built up under her initiative in order to carry out Pfizer’s objectives such as in the area of Intellectual Property Rights and related health policy.

Widya’s legal degree was obtained from Faculty of Law of the University of Indonesia and her master degree in Strategic Management from Prasetiya Mulya Business School, Jakarta. Currently she has been admitted in a Doctoral Program in Law at University of Pelita Harapan, Indonesia. She has also published an inspirational book of her own in 2015.

Early Confirmed Speakers:

  • Widyaretna Buenastuti, Public Affairs & Communications Director, Pfizer Indonesia
  • May Ng, Regulatory And Quality Consultant,Founder, ARQon Pte Ltd
  • Shibu Baburaj, Head, Regulatory Affairs, Sanofi-Aventis
  • Dimas Adityo, Compliance Director/Head of Ethics & Business Integrity, Sanofi Indonesia

To request the Latest Agenda & more details on the Programme, Speakers and their Presentationsby email, please click here>>

———————————————————————-

15% Early Bird Discount!
 
Standard Rate:£1,595
Discounted Rate: £1,355 (Save £240)
Discount Expires:28th April 2017
 
For Agenda, Information & Registration:
Priyesh Waghmare on +91(0)20.6527.2803 Email: pwaghmare@acieu.net or Register online >>>
Specialist Content: 
  • Regulatroy submissions implementation in eCTD format
  • The ASEAN Labelling Harmonisation Effort
  • Registration and approval timeline – combination products and exemptions
  • What’s new with clinical regulatory requirements in Asia Pacific?
  • Global trends vs. specific region’s updates for pharmacovigilance
  • Regulatory affairs support in providing advices to commercial team for inspection
  • Global Guidelines for the Development of Biologics

Why Attend?

Effectively interpret complicated regulatory guidelines to fast track your drug approval process

Asia’s regulatory systems are diverse, and oftentimes challenging to navigate. The regulatory agency in each Asian country has its own set of regulations and customary manner of conducting business. Thus, determining the most effective and efficient strategy to obtain approval for your pharmaceutical product from each regulatory body without sufficient knowledge and experience with Asian regulatory affairs can be a very difficult task.

To visit website, please click here
 
For Agenda, Information & Registration:
Priyesh Waghmare Tel: +91 (0)20.6527.2803 Email: pwaghmare@acieu.net


Speaking Opportunities:
Oby George Tel: +91 (0) 20 6527 2804 Email: ogeorge@acieu.net
—
Commercial & Sponsorship Opportunities:
Vivek Hankare Tel: +91 (0)20 6527 2804 Email: vhankare@acieu.net
Active Communications International Europe (ACI)

5/13 Great Suffolk Street, SE1 0NS London

International Pharma Regulatory Summit, 27th-28th July 2017, Singapore

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026